替吉奥胶囊姑息治疗晚期恶性肿瘤的疗效探讨

Curative Effect of Tegafur Gimeracil Oteracil Potassium Capsule in Palliative Treatment of Advanced Malignant Tumors

目的探讨晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效。方法回顾性选取2019年1月—2023年1月歙县人民医院肿瘤内科收治的60例晚期恶性肿瘤患者,依据治疗方法分为替吉奥组和对照组,每组30例。替吉奥组患者接受替吉奥胶囊姑息治疗,对照组患者接受卡培他滨治疗。统计分析两组患者临床疗效、血清肿瘤标志物水平[血清癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha-fetal protein,AFP)、糖类抗原199(carbohydrate antigen 199,CA199)]、疼痛程度[视觉模拟评分法(Visual Analog Scoring,VAS)]、生存质量[卡式评分标准(Card Rating Scale,KPS)、日常生活能力(Daily Living Ability,ADL)、工具性日常活动能力量表(Instrumental Daily Activity Ability Scale,IADL)、生活质量量表(Quality Of Life Scale,QOL)]、不良反应发生情况、生存期。结果替吉奥组患者的总缓解率83.33%高于对照组,差异有统计学意义(χ^(2)=9.320,P<0.05)。替吉奥组患者的血清AFP、CEA、CA199水平、VAS评分均低于对照组,KPS评分、ADL评分、IADL评分、QOL评分均高于对照组,差异有统计学意义(P<0.05)。替吉奥组患者的不良反应发生率10.00%低于对照组,差异有统计学意义(χ^(2)=4.344,P<0.05)。替吉奥组患者的无进展生存期长于对照组,差异有统计学意义(P<0.05)。结论晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效显著。

Objective To investigate the curative effect of tegafur gimeracil oteracil potassium capsule in palliative treatment of advanced malignant tumors.Methods A total of 60 patients with advanced malignant tumors admitted to the Medical Oncology Department of Shexian People's Hospital from January 2019 to January 2023 were retrospectively selected and divided into Tegafur group and control group according to treatment methods,with 30 cases in each group.The patients in the Tegafur group received Tegafur capsule for palliative treatment,and the patients in the control group received capecitabine.The clinical efficacy,serum tumor marker levels[serum carcinoembryonic antigen(CEA),alpha fetoprotein(AFP),carbohydrate antigen 199(CA199)],pain level[Visual Analog Scoring(VAS)],quality of life[Card Rating Scale(KPS),Daily Living Ability(ADL),and Instrumental Daily Activity Ability Scale(IADL),Quality Of Life Scale(QOL),occurrence of adverse reactions and survival time,were statistically analyzed between the two groups.Results The total remission rate of the Tegafur group was 83.33%,which was higher than that of the control group,and the difference was statistically significant(χ^(2)=9.320,P<0.05).For Tegafur group of patients with serum AFP,CEA,CA199 levels,VAS scores were lower than the control group,KPS score,ADL scores,IADL scores,QOL score were higher than the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the Tegafur group was 10.00%,which was lower than that in the control group,and the difference was statistically significant(χ^(2)=4.344,P<0.05).The progression-free survival time of patients in the Tegafur group was longer than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The curative effect of tegafur gimeracil oteracil potassium capsule in palliative treatment of advanced malignant tumors is remarkable.